We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
The current KYMR market cap is 2.09B. The company's latest EPS is USD -2.4048 and P/E is -14.24.
| Quarter End | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 9.47M | 16.51M | 4.73M | 47.89M | 10.29M |
| Operating Income | -45.33M | -43.38M | -57.51M | -19.31M | -52.91M |
| Net Income | -40.93M | -38.8M | -52.87M | -14.37M | -48.56M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 2.93M | 34.03M | 72.83M | 46.83M | 78.59M |
| Operating Income | -42.21M | -46.3M | -100.53M | -161.26M | -165.53M |
| Net Income | -41.25M | -54.64M | -100.22M | -154.81M | -146.96M |
| Quarter End | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 613.91M | 581.95M | 552.38M | 575.76M | 868.25M |
| Total Liabilities | 151.9M | 146.52M | 156.84M | 180.79M | 157.05M |
| Total Equity | 462.01M | 435.43M | 395.54M | 394.97M | 711.2M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 116.7M | 487.18M | 605.91M | 603.13M | 575.76M |
| Total Liabilities | 82.03M | 203.29M | 146.27M | 112.98M | 180.79M |
| Total Equity | -74.41M | 283.89M | 459.64M | 490.15M | 394.97M |
| Quarter End | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -43.97M | -79.22M | -110.87M | -102.83M | -39.59M |
| Investing | 24.58M | 60.42M | 120.93M | 139.89M | -330.61M |
| Financing | 1.16M | 2.46M | 2.26M | 4.19M | 353.76M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | 17.91M | 88.13M | -128.95M | -153.09M | -102.83M |
| Investing | -16.49M | -422.59M | -99.84M | 20.52M | 139.89M |
| Financing | 34.91M | 289.26M | 250.28M | 153M | 4.19M |
| Market Cap | 2.09B |
| Price to Earnings Ratio | -14.24 |
| Price to Sales Ratio | 26.63 |
| Price to Cash Ratio | 19.03 |
| Price to Book Ratio | 5.3 |
| Dividend Yield | - |
| Shares Outstanding | 61.11M |
| Average Volume (1 week) | 460.74k |
| Average Volume (1 Month) | 497.74k |
| 52 Week Change | 18.56% |
| 52 Week High | 45.31 |
| 52 Week Low | 9.60 |
| Spread (Intraday) | 0.06 (0.17%) |
| Company Name | Kymera Therapeutics Inc |
| Address |
corporation trust center wilmington, delaware 19801 |
| Website | https://www.kymeratx.com |
| Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
